Market revenue in 2023 | USD 12.5 million |
Market revenue in 2030 | USD 14.9 million |
Growth rate | 2.6% (CAGR from 2023 to 2030) |
Largest segment | Infectious diseases |
Fastest growing segment | Hematology |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Oncology, Prenatal Testing, Endocrinology, Other Applications, Hematology, Infectious Diseases |
Key market players worldwide | Roche, Abbott Laboratories, Qiagen NV, Bayer AG, Nova Biomedical, Danaher Corp, Nipro Corp, Bio-Rad Laboratories Inc, Agilent Technologies Inc, BioMerieux SA, OraSure Technologies Inc, Abaxis |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to point-of-care molecular diagnostics market will help companies and investors design strategic landscapes.
Infectious diseases was the largest segment with a revenue share of 93.6% in 2023. Horizon Databook has segmented the Kuwait point-of-care molecular diagnostics market based on oncology, prenatal testing, endocrinology, other applications, hematology, infectious diseases covering the revenue growth of each sub-segment from 2018 to 2030.
According to WHO, CVD, stroke, COVID-19, pneumonia, and cancer were major causes of death in Kuwait in 2022. The high burden of these diseases in the country is expected to fuel the demand for diagnostic testing and support the point-of-care molecular diagnostics market in Kuwait. Due to the pandemic, diagnostic device companies partnered with the market players to improve testing in Kuwait.
For instance, in March 2023, Mylab Discovery Solutions partnered with AstraGene, a diagnostic company, to develop automated point-of-care molecular diagnostics for Kuwait. Adoption of such strategies and the high burden of COVID-19 in the country is expected to improve the availability of immunoassays in the region.
Horizon Databook provides a detailed overview of country-level data and insights on the Kuwait point-of-care molecular diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into Kuwait point-of-care molecular diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account